NO992944L - Active ingredient for the delivery of apomorphine in the oral cavity - Google Patents

Active ingredient for the delivery of apomorphine in the oral cavity

Info

Publication number
NO992944L
NO992944L NO992944A NO992944A NO992944L NO 992944 L NO992944 L NO 992944L NO 992944 A NO992944 A NO 992944A NO 992944 A NO992944 A NO 992944A NO 992944 L NO992944 L NO 992944L
Authority
NO
Norway
Prior art keywords
apomorphine
oral cavity
delivery
active ingredient
oblate
Prior art date
Application number
NO992944A
Other languages
Norwegian (no)
Other versions
NO992944D0 (en
Inventor
Karsten Cremer
Original Assignee
Lohmann Therapie Syst Lts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lohmann Therapie Syst Lts filed Critical Lohmann Therapie Syst Lts
Publication of NO992944L publication Critical patent/NO992944L/en
Publication of NO992944D0 publication Critical patent/NO992944D0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Abstract

Legemiddeltilberedning med flate, folie-, papir- eller oblataktige administreringsformer for applisering og frigjøring av virkestoffer i munnhulen, kjennetegnet ved et innhold av apomorfin eller et av dens terapeutisk egnede salter.Pharmaceutical preparation with flat, foil, paper or oblate forms of administration for the application and release of active substances in the oral cavity, characterized by a content of apomorphine or one of its therapeutically suitable salts.

NO992944A 1996-12-16 1999-06-16 Active ingredient for the delivery of apomorphine in the oral cavity NO992944D0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19652268A DE19652268C2 (en) 1996-12-16 1996-12-16 Medicinal preparation for the release of apomorphine in the oral cavity
PCT/EP1997/006529 WO1998026763A1 (en) 1996-12-16 1997-11-21 Active substance carrier for releasing apomorphine into the buccal cavity

Publications (2)

Publication Number Publication Date
NO992944L true NO992944L (en) 1999-06-16
NO992944D0 NO992944D0 (en) 1999-06-16

Family

ID=7814859

Family Applications (1)

Application Number Title Priority Date Filing Date
NO992944A NO992944D0 (en) 1996-12-16 1999-06-16 Active ingredient for the delivery of apomorphine in the oral cavity

Country Status (8)

Country Link
EP (1) EP0959875A1 (en)
JP (1) JP2001506612A (en)
KR (1) KR20000057627A (en)
AU (1) AU746373B2 (en)
CA (1) CA2274893A1 (en)
DE (1) DE19652268C2 (en)
NO (1) NO992944D0 (en)
WO (1) WO1998026763A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9803240D0 (en) 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
US6596298B2 (en) 1998-09-25 2003-07-22 Warner-Lambert Company Fast dissolving orally comsumable films
US6291471B1 (en) 1998-12-17 2001-09-18 Abb Holdings, Inc. Use of apomorphine for the treatment of organic erectile dysfunction in males
ATE445335T1 (en) 1998-12-23 2009-10-15 Sinai School Medicine INHIBITORS FOR SUPPRESSING BITTER TASTE
US7314716B2 (en) 1999-11-19 2008-01-01 Mount Sinai School Of Medicine Gustducin γ subunit materials and methods
US7067116B1 (en) 2000-03-23 2006-06-27 Warner-Lambert Company Llc Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1
USRE44145E1 (en) 2000-07-07 2013-04-09 A.V. Topchiev Institute Of Petrochemical Synthesis Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties
US8541021B2 (en) 2001-05-01 2013-09-24 A.V. Topchiev Institute Of Petrochemical Synthesis Hydrogel compositions demonstrating phase separation on contact with aqueous media
US8206738B2 (en) 2001-05-01 2012-06-26 Corium International, Inc. Hydrogel compositions with an erodible backing member
US20050215727A1 (en) 2001-05-01 2005-09-29 Corium Water-absorbent adhesive compositions and associated methods of manufacture and use
US8840918B2 (en) 2001-05-01 2014-09-23 A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences Hydrogel compositions for tooth whitening
US8728445B2 (en) 2001-05-01 2014-05-20 A.V. Topchiev Institute Of Petrochemical Synthesis, Russian Academy Of Sciences Hydrogel Compositions
DE10252726B4 (en) * 2002-11-13 2008-05-08 Lts Lohmann Therapie-Systeme Ag Multilayer transmucosal therapeutic system
US20060035008A1 (en) * 2002-11-14 2006-02-16 Givaudan Sa Edible film containing food acid
KR100945741B1 (en) * 2003-01-16 2010-03-05 부광약품 주식회사 Oral spray preparation of apomorphine hydrochloride
US8658201B2 (en) * 2004-01-30 2014-02-25 Corium International, Inc. Rapidly dissolving film for delivery of an active agent
US20050281757A1 (en) * 2004-06-17 2005-12-22 Sayed Ibrahim Oral care film
AU2010204986B2 (en) 2009-01-14 2016-06-02 Corium International, Inc. Transdermal administration of tamsulosin
ES2699077T3 (en) * 2009-06-12 2019-02-07 Sunovion Pharmaceuticals Inc Sublingual Apomorphine
NZ612686A (en) 2010-12-16 2015-11-27 Cynapsus Therapeutics Inc Sublingual films
US10806703B2 (en) * 2012-01-20 2020-10-20 Lts Lohmann Therapie-System Ag Transmucosal administration system for a pharmaceutical drug
EP3068396B1 (en) * 2013-11-11 2019-05-08 Impax Laboratories, Inc. Rapidly disintegrating formulations and methods of use
EP3285771A4 (en) 2015-04-21 2018-12-05 Sunovion Pharmaceuticals Inc. Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3972995A (en) * 1975-04-14 1976-08-03 American Home Products Corporation Dosage form
DE2746414A1 (en) * 1977-10-15 1979-04-26 Gerlach Eduard Chem Fab Foil-like tape for dispensing measured amts. of substance - consisting of the substance, binding agent and adjuvants, tape length being proportional to weight of substance
ATE189121T1 (en) * 1994-04-22 2000-02-15 Pentech Pharmaceuticals Inc SUBLINGUAL DOSAGE FORMS CONTAINING APOMORPHINE FOR USE IN THE TREATMENT OF ERECTILE DYSFUNCTION
FR2732896B1 (en) * 1995-04-11 1997-06-13 Prographarm Lab TRANSDERMAL PHARMACEUTICAL FORM FOR PERCUTANEOUS ADMINISTRATION OF APOMORPHINE

Also Published As

Publication number Publication date
AU746373B2 (en) 2002-04-18
DE19652268C2 (en) 2000-06-29
WO1998026763A1 (en) 1998-06-25
KR20000057627A (en) 2000-09-25
DE19652268A1 (en) 1998-06-18
JP2001506612A (en) 2001-05-22
AU5654798A (en) 1998-07-15
CA2274893A1 (en) 1998-06-25
EP0959875A1 (en) 1999-12-01
NO992944D0 (en) 1999-06-16

Similar Documents

Publication Publication Date Title
NO992944L (en) Active ingredient for the delivery of apomorphine in the oral cavity
IT8719064A0 (en) TABLET FOR PHARMACEUTICAL USE SUITABLE FOR THE RELEASE OF ACTIVE SUBSTANCES AT SUBSEQUENT TIMES.
NO992907D0 (en) Flat drug preparation for the application and release of buprenorphine or another pharmacologically comparable substance in the oral cavity and process for its preparation
DE69100991T2 (en) PHARMACEUTICAL FORMULATIONS.
AU1227899A (en) Osmotic medicament releasing system
DK0934058T3 (en) Stable drug form with benzimidazole derivatives as active substance for oral administration and method of preparation thereof
DE69918310D1 (en) TABLET WITH DELAYED RELEASE CONTAINING A BLOOD GLUCOSE-LOWING ACTIVE SUBSTANCE AND AN ANI-HYPERGLYZEMIC ACTIVE SUBSTANCE
GR1002564B (en) Oral solid pharmaceutical form and administration therefor
EE04800B1 (en) Oral dosage form for acid unstable active ingredient, unit dosage form, method of preparation and use, and method for oral dosage form
BG66095B1 (en) Pregelatinized starch in a controlled release preparation
BR9917012A (en) Matrix tablet, allowing prolonged release of gliclazide, after oral administration
WO1998004249A3 (en) Tramadol multiple unit formulations
HUP9904174A2 (en) Pharmaceutical composition for transdermic delivery
IL90435A (en) 4-(quinoline-2-yl-methoxy) phenylacetic acid derivatives, their preparation and pharmaceutical compositions containing them
AU2506388A (en) Azelastine-containing medicaments for application in the nose and/or at the eye
AR026968A1 (en) A MATRIX TABLET THAT ALLOWS THE PROLONGED TRIMETAZIDINE RELEASE AFTER YOUR ADMINISTRATION BY ORAL ROUTE
CA2136404A1 (en) Mucoadhesive, therapeutic or hygienic solid composition for application on oral or nasal mucosa
WO2002024203A3 (en) Controlled release formulations for oral administration
ES2130081A1 (en) Coated trimebutine maleate tablet
ES2010466A6 (en) Effervescent tablet containing diclofenac
AU6788687A (en) A pharmaceutical which can be administered nasally, a process for its preparation, and its use
GR1000316B (en) Process for the preparation of a compound with gastric inhibitopy effect
AR022621A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING DEOXIPEGANINE FOR THE TREATMENT OF NICOTINE DEPENDENCE
AU3278800A (en) Pharmaceutical composition containing desoxypeganine for the treatment of drug dependence
ATE169818T1 (en) CARBAMAZEPINE DELAYED RELEASE MEDICINAL FORM

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application